ExoZymes Inc. reports NCT production scale-up using exozymes

ExoZymes Inc. filed a current report to announce that it has issued a press release about scaling up production of NCT using its exozymes technology.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

ExoZymes Inc. filed a current report to announce that it has issued a press release about scaling up production of NCT using its exozymes technology. The company classifies this as an "Other Event," highlighting operational progress rather than a financial update or major transaction. The press release, dated December 11, 2025, is furnished as an exhibit to the report, indicating the company wants investors informed about this step in its production capabilities while remaining listed on the Nasdaq Capital Market under the symbol EXOZ.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ExoZymes Inc. (EXOZ) announce in this 8-K filing?

ExoZymes Inc. reported that it issued a press release related to the scale up of NCT production using exozymes, classifying this disclosure as an "Other Event."

What is the main operational update from ExoZymes Inc. (EXOZ)?

The main operational update is that ExoZymes Inc. is scaling up NCT production using its exozymes technology, as described in a press release dated December 11, 2025.

Does this ExoZymes (EXOZ) filing include financial results or earnings data?

No. The report focuses on an "Other Event" related to NCT production scale up and does not present financial results or earnings data.

Where can investors find more details about ExoZymes’ NCT production update?

More details are contained in the press release furnished as Exhibit 99.1, titled "Press Release dated December 11, 2025, related to NCT production."

On which exchange is ExoZymes Inc. (EXOZ) listed and what is its trading symbol?

ExoZymes Inc. is listed on the Nasdaq Capital Market and its common stock trades under the symbol EXOZ.

What exhibits did ExoZymes (EXOZ) include with this 8-K?

ExoZymes included Exhibit 99.1, a press release related to NCT production, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 12/11/2025 - 07:43 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

December 11, 2025

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada

001-42204

83-4550057

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (626) 415-1488

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		EXOZ		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 — Other Events.

Attached is a press release eXoZymes Inc. dated December 11, 2025, related to the scale up of NCT production using exozymes.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibits		Description of Exhibit

99.1		Press Release dated December 11, 2025, related to NCT production.

104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 12, 2025	EXOZYMES INC.

	By	/s/ Fouad Nawaz
		Fouad Nawaz,
		Vice President, Finance

Source: View Original Filing on SEC EDGAR